RxDoctor Payments DataLook up a doctor →

Brian Lake, DO

Endocrinology, Diabetes & Metabolism · Largo, FLNPI 1295887040

Payments from drug & device makers

$887,600in general payments, 2019–2025

Across 2,121 payments — averaging $418.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$296K
  • Novo Nordisk$198K
  • Abbott$152K
  • Medtronic$116K
  • Sanofi-aventis U.S. LLC$45K
  • AstraZeneca$36K
  • plus $45K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC586$295,767
Novo Nordisk324$198,395
Abbott236$151,610
Medtronic(2 entities)234$115,786
Sanofi-aventis U.S. LLC131$45,492
AstraZeneca134$35,520
Tandem Diabetes Care, Inc.27$15,852
Dexcom, Inc.61$13,587
Cequr Corporation6$5,357
Insulet Corporation18$2,052
Bayer43$1,045
Amgen(2 entities)32$970
Novartis20$481
Boehringer Ingelheim24$475
IBSA Pharma Inc.20$434
Antares Pharma, Inc.18$360
Corcept Therapeutics18$351
Xeris Pharmaceuticals, Inc.18$318
Amneal Pharmaceuticals LLC15$273
Merck17$265
Mannkind Corporation11$224
Johnson & Johnson9$216
BETA Bionics, Inc.5$211
Amarin Pharma, Inc.10$206
AbbVie(2 entities)9$203
Radius Health, Inc.9$153
W. L. Gore & Associates, Inc.1$147
Recordati_rare_diseases_inc.5$137
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$132
Zealand Pharma US, Inc.6$132
Nevro Corp.6$130
Renalytix AI, Inc.4$93
Neurocrine Biosciences, Inc.3$85
Ascendis Pharma Endocrinology Inc3$83
Ascensia Diabetes Care US Inc.4$81
Halozyme Inc4$78
Eisai Inc.3$68
Madrigal Pharmaceuticals2$65
Sequel Med Tech, LLC3$64
Kowa Pharmaceuticals America, Inc.4$62
RGH Enterprises LLC2$54
GSK3$51
EUSA Pharma (US) LLC2$44
Companion Medical, Inc.2$39
Esperion Therapeutics, Inc.2$39
Clarus Therapeutics Inc.3$38
Bigfoot Biomedical Inc1$35
Valeritas, Inc.1$28
Shire North American Group Inc2$28
Kyowa Kirin, Inc.1$28
Amphastar Pharmaceuticals, Inc.1$26
Averitas Pharma Inc.1$25
Regeneron Healthcare Solutions, Inc.1$24
Acerus Pharmaceuticals Corporation1$23
Cook Medical LLC1$22
Pfizer1$21
Biohaven Pharmaceuticals, Inc.1$20
Verity Pharmaceuticals Inc.1$19
Globus Medical1$18
Tolmar, Inc.1$15

How this compares

$887,600 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024
$219,146
Medicare patients
667
Services billed
2,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Largo

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →